Bio-Rad Laboratories (BIO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Bio-Rad Laboratories

NYSE•Healthcare•Medical Devices

$386.11-1.79(<0.01%)Market closed

Market Cap

$10.23B

P/E

46.0x

P/S

4.0x

P/B

1.4x

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

How this company scores

AverageMetricSide Score: 48/100

Strongest: Balance Sheet & Red Flags (19/25); weakest: Profitability (7/25).

Profitability7/25

Growth10/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality12/25

Strengths

Low leverageConsistent free cash flowImproving leverageImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 46.0x5y range 1.5x – 46.0x

Currently above its 6-quarter median.

P/S · 4.0x5y range 2.6x – 4.0x

Currently near its 20-quarter median.

P/B · 1.4x5y range 0.7x – 1.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 71.7% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.2x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $10.23B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.59B
Q. Revenue: $651.00M
TTM EBITDA: $53.10M
TTM Op. Income: $53.10M
Q. Op. Income: $72.60M
TTM Net Income: $222.40M
Q. Net Income: $371.40M
EPS: N/A
Shares Out.: $26.75M

$2.59B in TTM revenue grew 1.4% YoY, reaching $651.00M last quarter. TTM EBITDA of $53.10M and TTM operating income of $53.10M show growth is flowing through to the bottom line. TTM net income of $222.40M means revenue is converting into profit. Over the past year, TTM revenue is up 1% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 11.2%
Op. Margin: 11.2%
Net Margin: 57.1%

Op. margin of 11.2% is down 0.7% YoY — costs are rising relative to revenue. Net margin at 57.1% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 46.0x
P/S Ratio: 4.0x
P/B Ratio: 1.4x

At 46.0x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 4.0x and P/B of 1.4x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 4 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $10.25B
Cash: $517.00M
Long-Term Debt: $803.00M
Book Value: $7.17B
D/E Ratio: 0.1
Debt/EBITDA: 11.1

With $10.25B in assets and $803.00M in long-term debt, D/E is 0.1and book value is $7.17B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $98.70M
TTM Free Cash Flow: $353.10M
FCF Margin: 13.6%
FCF / Net Income: 1.6

TTM FCF of $353.10M on $98.70M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.